All GLG News Analyses Filed Under: Infectious Disease
Posted September 24, 2007
GlaxoSmithKline's Rotarix(R) Could Be co-administered with routine infant vaccines recommended in the U.S. subject to the FDA approval
Analysis of: New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With Other Routine Infant Vaccines In The U.S. | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Analysis of: New Data Show That GlaxoSmithKline's Rotarix(R) Could Be Given With Other Routine Infant Vaccines In The U.S. | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Release of a news regarding the co-administration of Rotarix(R), an oral candidate vaccine for infants to prevent rotavirus gastroenteritis, with routine vaccines for two and four months old immunization stage is definitely an interesting development. The result of the clinical trials indicating...
Posted September 24, 2007
Using New Antibiotic Drug Combo the treatment time for Tuberculosis could be reduced
Analysis of: FDA Approves Expanded Label For FluMist(R) To Include Children Two To Five Years Of Age | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Analysis of: FDA Approves Expanded Label For FluMist(R) To Include Children Two To Five Years Of Age | www.medicalnewstoday.com
Author: GLG Member Program Contributor
The news is very important for showing the effectiveness of this drug to reduce the suffering of TB patients, and also to prevent from further transmission to others. The disease is epidemic in the developing world, where a cry for medical treatment in evident. This news may appear as a relief for such...
Posted September 24, 2007
Stregnths and weaknesses of daptomycin use for MRSA infections
Analysis of: Cubicin(R) receives European approval to expand use to treating two additional types of life-threatening hospital infections | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Cubicin(R) receives European approval to expand use to treating two additional types of life-threatening hospital infections | www.pipelinereview.com
Author: GLG Member Program Contributor
* New class of antibiotic with activity against MRSA that has been used in the US to treat sepsis and severe infections. * As or more expensive than other drug regimens for the patient populations indicated. * Resistance to daptomycin has been reported in MRSA and enterococci. * Has a role, but generally...
Posted September 24, 2007
Interesting peptide antibiotic with cidal activity, but potential toxic side effects on eukaryotic cells in vitro
Analysis of: Oritavancin Demonstrates Potent And Rapid In Vitro Activity Against MRSA, VRE And Other Strains Of Resistant Bacteria | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Analysis of: Oritavancin Demonstrates Potent And Rapid In Vitro Activity Against MRSA, VRE And Other Strains Of Resistant Bacteria | www.medicalnewstoday.com
Author: GLG Member Program Contributor
* Some interesting in vitro data regarding cidal/killing activity of oritavancin, another peptide antibiotic in the same class as vancomycin. * No significant animal models to date. * One study has shown some toxic effects on eukaryotic cells in vitro. * Remains to be determined if this antibiotic...
Posted September 24, 2007
A light in the darkness?
Analysis of: Oritavancin Demonstrates Potent And Rapid In Vitro Activity Against MRSA, VRE And Other Strains Of Resistant Bacteria | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Analysis of: Oritavancin Demonstrates Potent And Rapid In Vitro Activity Against MRSA, VRE And Other Strains Of Resistant Bacteria | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Antimicrobial resistance is becoming more and more prevalent. If this agent holds up in clinical trails it will be a needed brekthrough.
Posted September 24, 2007
It's About Time
Analysis of: FDA Okays FluMist Vaccine For Young Children | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Analysis of: FDA Okays FluMist Vaccine For Young Children | www.medicalnewstoday.com
Author: GLG Member Program Contributor
- flumist will prove attractive to parents of young children, because young children are the group most traumatized by injections
Posted September 21, 2007
Good start if needed
Analysis of: Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at Low Dosage | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at Low Dosage | www.pipelinereview.com
Author: GLG Member Program Contributor
Concerns abound re the possible issue of Avain flu. How siginifcant this will be in unclear in the near future. Having a vaccine is important,though.
Posted September 17, 2007
A welcome but expensive addition
Analysis of: Cubicin(R) receives European approval to expand use to treating two additional types of life-threatening hospital infections | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Cubicin(R) receives European approval to expand use to treating two additional types of life-threatening hospital infections | www.pipelinereview.com
Author: GLG Member Program Contributor
MRSA is a growing problem. The more drugs available the better. Price, at least in the US, is an issue.
Posted September 7, 2007
Daptomycin approved in Europe for MRSA bacteremia and right sided endocarditis
Analysis of: Cubicin(R) receives European approval to expand use to treating two additional types of life-threatening hospital infections | www.pipelinereview.com
Author: GLG Member Program Contributor
Analysis of: Cubicin(R) receives European approval to expand use to treating two additional types of life-threatening hospital infections | www.pipelinereview.com
Author: GLG Member Program Contributor
The large study comparing daptomycin to a comparator group of either vancomycin plus gent or a semi-synthetic penicillin plus gent showed no statistically significant differences in responses for Staph aureus bacteremia. The subgroup with MRSA, which was a pre-determined analysis, did show a trend to...
Posted September 6, 2007
Potential Market for this Vaccine is Huge
Analysis of: FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox | www.therapeuticsdaily.com
Author: GLG Member Program Contributor
Previous
Page :
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Next111 to
120
of 222Analysis of: FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox | www.therapeuticsdaily.com
Author: GLG Member Program Contributor
As someone who has been involved in the field of disaster preparedness, and response to nuclear, biological and chemical (NBC) weapons - and now terrorist weapons for over 25 years, I say the demand for this vaccine COULD be enormous - or maybe not
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
St John's Wort 'as good as Prozac'
ukpress.google.com
Pfizer shifts focus to cancer and biotech drugs
ap.google.com
Genentech Set Back by Cancer-Drug Study
online.wsj.com
PixelOptics focuses on new lens
www.roanoke.com
C. Difficile And Antibiotics Not Necessarily Linked, Study Finds
www.sciencedaily.com
St. John's Wort vs Prozac
October 13, 2008
Signs That the Is Party Over?
October 10, 2008
A new lens for computer users?
October 6, 2008
Need to use these meds correctly
October 6, 2008
Not All That Shines is Gold
October 2, 2008

